DoseMe today announced that DoseMeRx – the leading clinical decision support tool for precision dose calculations – has been selected for assessment by the University Hospitals of Leicester NHS Trust to optimize the dosing of vancomycin used in intensive care patients to treat MRSA blood stream infections.
The project will evaluate implementing personalized vancomycin dosing using DoseMeRx into routine clinical practice at the 22-bed adult and eight-bed pediatric ICUs at Glenfield Hospital.
“Selecting the optimal dose to achieve target vancomycin levels in the blood is complex and this is further complicated for critically-ill patients, as disease and physiological changes affect drug absorption” said Robert McLeay, PhD, Chief Scientific Officer, DoseMe.
“Current dosing approaches rely on the physicians experience and knowledge. Dosage calculators like DoseMeRx have been shown to lower adverse-drug events by more than 60%, increase drug effectiveness, and significantly improve clinical performance in reaching therapeutic ranges. Even more spectacularly, in some patient groups, mortality can be halved.
“DoseMeRx is used internationally across a wide range of hospital patient populations. We’re pleased to have been selected by Glenfield Hospital to extend precision dosing into even broader clinical practice by supporting their physicians to extend optimal personalized dosing into the challenging environment of the intensive care unit,” said McLeay
DoseMeRx supports several classes of drugs in addition to vancomycin, including antibiotics, anti-coagulants, anti-fungals, immunosuppressants and chemotherapeutic agents for adults and pediatrics. It is available for use on the desktop, mobile devices, and integrates into all major EHRs.
To learn more about how DoseMeRx dosage calculator optimizes vancomycin dosing watch our online demo, read more about our platform or start a free two-week trial to experience the benefits of DoseMeRx at your hospital.
Originally published in The Health Foundation: Optimizing the treatment of MRSA through use of computer models to personalize vancomycin dosing